Kip Guy, PhD

  • Dean, University of Kentucky College of Pharmacy
REQUEST AN APPOINTMENT

About

Faculty Rank

  • Professor

Training & Education

Fellowship

1996-1998: University of Texas Southwestern Medical Center (UTSWMC) Dallas, TX, Postdoctoral Fellowship in Cellular Biology with Drs. Brown and Goldstein

Degree

1991-1996: The Scripps Research Institute (TSRI), La Jolla, CA, Ph.D. in Organic Chemistry with Dr. K. C. Nicolaou
1995: The Woods Hole Research Institute, Woods Hole, MA, Physiology: Cellular and Molecular Biology Course
1986-1990: Reed College, Portland, OR, B.A. in Chemistry

Research

Research Focus

Chemical biology and drug discovery.

Programs

Translational Oncology

College & Department

Contact Information

789 S. Limestone
Lexington, KY 40536
United States

Phone
859-257-5290
Email
kip.guy@uky.edu

Publications

  1. Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase
    Scott, D. C.; Hammill, J. T.; Min, J.; Rhee, D. Y.; Connelly, M.; Sviderskiy, V. O.; Bhasin, D.; Chen, Y.; Ong, S.-S.; Chai, S. C.; Goktug, A. N.; Huang, G.; Monda, J. K.; Low, J.; Kim, H. S.; Paulo, J. A.; Cannon, J. R.; Shelat, A. A.; Chen, T.; Kelsall, I. R.; Alpi, A. F.; Pagala, V.; Wang, X.; Peng, J.; Singh, B.; Harper, J. W.; Schulman, B. A.; Guy, R. K. Nature Chem. Biol., 2017, 13(8), 850-857. PMCID: PMC5577376.
  2. Discovery of a Diaminopyrimidine FLT3 Inhibitor Active Against Acute Myeloid Leukemia
    Jarusiewicz, J. A.; Jeon, J. Y.; Connelly, M. C.; Chen, Y.; Yang, L.; Baker, S. D.; Guy, R. K. ACS Omega, 2017, ao7b00144, PMCID: PMC5452050.
  3. Establishing A Preclinical Multidisciplinary Brain Tumor Board
    Nimmervoll, B.; Boulos, N.; Bianski, B.; Dapper, J.; DeCuypere, M.; Shelat, A; Terranova, S.; Gilbertson, H.; Gajjar, A.; Patel, Y.; Freeman, B.; Onar-Thomas, A.; Stewart, C.; Roussel, M.; Guy, R. K.; Merchant, T.; Calabrese, C.; Wright, K.; Gilbertson, R. Clin. Cancer. Res. 2018, 24(7), e0006157. PMCID: PMC5884708.
  4. Evaluation of Artemisinins for the Treatment of Acute Myeloid Leukemia
    Drenberg, C. D.; Buaboonnam, J.; Orwick, S. J.; Hu, S.; Li, L.; Fan, Y.; Shelat, A. A.; Guy, R. K.; Rubnitz, J.; Baker, S. D. Cancer Chemother. Pharmacol. 2016, 77(6), 1231-1243. PMCID: PMC4918815.
  5. Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents
    Min, J.; Guo, K.; Suryadevara, P. K.; Zhu, F.; Holbrook, G.; Chen, Y.; Feau, C.; Young, B. M.; Lemoff, A.; Connelly, M. C.; Kastan, M. B.; Guy, R. K. J. Med. Chem. 2016, 59(2), 559-577. PMCID: Not applicable.
  6. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.
    Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. Cancer Cell. 2011 Sep 13;20(3):384-99. PubMed PMID: 21907928; PubMed Central PMCID: PMC3172881.
  7. Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms.
    Geistlinger TR, McReynolds AC, Guy RK. Chem Biol. 2004 Feb;11(2):273-81. PubMed PMID: 15123288.
  8. Inactivation of the p53 pathway in retinoblastoma.
    Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA. Nature. 2006 Nov 2;444(7115):61-6. PubMed PMID: 17080083.
  9. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.
    Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF. Cancer Cell. 2014 Apr 14;25(4):516-29. PubMed PMID: 24684846; PubMed Central PMCID: PMC3994669.